S&P Futures
4,362.00 +1.00 (+0.02%) Dow Futures
34,232.00 0.00 (0.00%) Nasdaq Futures
14,870.25 +0.75 (+0.01%) Russell 2000 Futures
1,789.90 -2.80 (-0.16%) Crude Oil
90.39 +0.36 (+0.40%) Gold
1,943.10 -2.50 (-0.13%)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.50 |
| Open | 6.50 |
| Bid | 5.50 x 900 |
| Ask | 7.94 x 1000 |
| Day's Range | 6.50 - 7.00 |
| 52 Week Range | 2.11 - 13.17 |
| Volume | |
| Avg. Volume | 12,358 |
| Market Cap | 30.081M |
| Beta (5Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.56 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CRBP
Related Research
- Corbus Pharmaceuticals HoldingsAnalyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.RatingFair ValueEconomic Moat4 days agoArgus Research
PR NewswireCorbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held in Boston, MA October 11-15, 2023.
- PR Newswire
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.
- PR Newswire
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.
